Evidence map›Paper›PMID 31623333›Full record

ArticlePharmaceutics2019

Development of a Stable Respiratory Syncytial Virus Pre-Fusion Protein Powder Suitable for a Core-Shell Implant with a Delayed Release in Mice: A Proof of Concept Study.

Max Beugeling, Katie Amssoms, Freek Cox, Ben De Clerck, Ellen Van Gulck, Jeroen A Verwoerd, Guenter Kraus, Dirk Roymans, Lieven Baert, Henderik W Frijlink and 1 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Pharmaceutics, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed.

  1. Article
  2. Article
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors.

Max BeugelingDepartment of Pharmaceutical Technology and Biopharmacy, University of Groningen, Antonius Deusinglaan 1, 9713 AV Groningen, The Netherlands. m.beugeling@rug.nl.
Katie AmssomsDrug Product Development_Developability, Janssen Research and Development, a Division of Janssen Pharmaceutica NV, Turnhoutseweg 30, 2340 Beerse, Belgium. kamssoms@its.jnj.com.
Freek CoxJanssen Vaccines & Prevention B.V., Archimedesweg 4-6, 2333 CN Leiden, The Netherlands. FCox@its.jnj.com.
Ben De ClerckJanssen Infectious Diseases and Vaccines, Janssen Research and Development, a Division of Janssen Pharmaceutica NV, Turnhoutseweg 30, 2340 Beerse, Belgium. BDECLERC@its.jnj.com.
Ellen Van GulckJanssen Infectious Diseases and Vaccines, Janssen Research and Development, a Division of Janssen Pharmaceutica NV, Turnhoutseweg 30, 2340 Beerse, Belgium. EVANGULC@its.jnj.com.
Jeroen A VerwoerdDepartment of Pharmaceutical Technology and Biopharmacy, University of Groningen, Antonius Deusinglaan 1, 9713 AV Groningen, The Netherlands. jeroen_verwoerd@hotmail.com.
Guenter KrausJanssen Infectious Diseases and Vaccines, Janssen Research and Development, a Division of Janssen Pharmaceutica NV, Turnhoutseweg 30, 2340 Beerse, Belgium. gkraus@its.jnj.com.
Dirk RoymansJanssen Infectious Diseases and Vaccines, Janssen Research and Development, a Division of Janssen Pharmaceutica NV, Turnhoutseweg 30, 2340 Beerse, Belgium. DROYMANS@its.jnj.com.
Lieven BaertJalima Pharma bvba, Jozef Van Walleghemstraat 11, 8200 Brugge, Belgium. lieven.baert@jalimapharma.com.
Henderik W FrijlinkDepartment of Pharmaceutical Technology and Biopharmacy, University of Groningen, Antonius Deusinglaan 1, 9713 AV Groningen, The Netherlands. h.w.frijlink@rug.nl.
Wouter L J HinrichsDepartment of Pharmaceutical Technology and Biopharmacy, University of Groningen, Antonius Deusinglaan 1, 9713 AV Groningen, The Netherlands. w.l.j.hinrichs@rug.nl.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Currently, there is an increasing interest to apply pre-fusion (pre-F) protein of respiratory syncytial virus (RSV) as antigen for the development of a subunit vaccine. A pre-F-containing powder would increase the flexibility regarding the route of administration. For instance, a pre-F-containing powder could be incorporated into a single-injection system releasing a primer, and after a lag time, a booster. The most challenging aspect, obtaining the booster after a lag time, may be achieved by incorporating the powder into a core encapsulated by a nonporous poly(dl-lactic-

Indexed as

biphasic pulsatile releasecontrolled releasefreeze-dried powderfusion proteinpoly(dl-lactic-co-glycolic acid)pre-fusionrespiratory syncytial virussingle-injection vaccine

Identifiers

PMID31623333
PMCPMC6835792

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.